Deakin UniversityBrowse

File(s) not publicly available

A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

conference contribution
posted on 2018-05-20, 00:00 authored by Mustafa KhasrawMustafa Khasraw, Kerrie Leanne McDonald, Mark Rosenthal, Zarnie Lwin, David M Ashley, Helen Wheeler, Elizabeth Barnes, Eng-Siew Koh, Matthew C Foote, Michael Buckland, Lauren Fisher, Robyn Leonard, Merryn Hall, Sonia Yip, John Simes
A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).

History

Volume

36

Issue

15

Publisher

AMER SOC CLINICAL ONCOLOGY

Publisher DOI

ISSN

0732-183X

eISSN

1527-7755

Language

English

Author URL

Publication classification

E3 Extract of paper

Title of proceedings

JOURNAL OF CLINICAL ONCOLOGY

Usage metrics

Read the peer-reviewed publication

A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
Research PublicationsResearch Publications

Categories

Keywords

Science & TechnologyLife Sciences & BiomedicineOncology

Licence

All Rights Reserved

Exports